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Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is
widely used as a chemotherapy combination for the adjuvant treat-
ment of breast cancer. The ‘classical’ CMF regimen comprises 6
cycles of oral cyclophosphamide (100 mg m–2 day–1) days 1–14
with intravenous (i.v.) methotrexate (40 mg m–2) and i.v. 5-fluoro-
uracil (600 mg m–2) on days 1 and 8, repeated every 28 days
(Bonadonna and Valagussa, 1981). To improve the therapeutic
index, the dosages, schedule and route of administration of CMF
have been widely varied. Several trials have suggested that
relapse-free survival and overall survival not only depend on the
total dose of the cytotoxic drugs actually administered, but the
more so on the dose intensity, i.e. the amount of drug given per
unit of time (Bonadonna and Valagussa, 1981; Hryniuk and Bush,
1984; Hryniuk and Levine, 1986; Hryniuk et al, 1987; Tannock 
et al, 1988; Ang et al, 1989; Engelsman et al, 1991; Wood et al,
1994).
Based on the assumptions that compliance with oral cyclophos-
phamide would be less than when the drug was given i.v. and that
variability in absorption of cyclophosphamide by the oral route
could lead to variable bio-availability, several studies have used
i.v. CMF schedules. A potential advantage of the i.v. regimens is
the easier possibility of a combination with a haematopoietic
growth factor such as granulocyte colony-stimulating factor (G-
CSF). G-CSF stimulates the recovery of granulocytes after
chemotherapy. G-CSF has been used to enhance dose intensity by
shortening the interval between cycles or by increase in dosage
(Bronchud et al, 1989; Neidhart et al, 1989; Crawford et al, 1991;
Lieschke and Burgess, 1992; Biesma et al, 1992; De Graaf et al,
1996; Ribas et al, 1996).
The aim of the present prospective study was to evaluate the
feasibility of a regimen with an intensified i.v. CMF schedule
supported by G-CSF and administered every 3 weeks, reaching a
projected dose intensity (DI) of 143% compared to ‘classical’
CMF.
PATIENTS AND METHODS
Eligible were premenopausal women who were considered for
adjuvant chemotherapy with CMF. Primary treatment consisted of
a modified radical mastectomy or breast-conserving surgery.
Patients were ineligible if they had renal impairment (serum
creatinine level > 120 mmol l–1), abnormal liver function (bilirubin
level > 25 mmol l–1) or abnormal baseline marrow reserve (leuco-
cyte count < 3.0 ´ 109 l–1, platelet count < 150 ´ 109 l–1).
Patients received cyclophosphamide 750 mg m–2, methotrexate
40 mg m–2 and 5-fluorouracil 600 mg m–2, all i.v. on days 1 and 8,
repeated every 21 days, for a total of 6 cycles. The administration
of the chemotherapy on days 1 and 8 were defined as two separate
courses (A and B), so patients received a total of 12 courses. G-
CSF (Neupogen, Roche, Mijdrecht, The Netherlands) was admin-
istered in a dose of 300 mg subcutaneously once a day on days
9–18 of each cycle. Blood counts were collected on days 1 and 8
before i.v. administration of the chemotherapeutic drugs. The
chemotherapy was administered if the leucocyte count was 
> 2.5 ´ 109 l–1 on day 1 or > 1.0 ´ 109 l–1 on day 8 and if the platelet
count was > 75 ´ 109 l–1 on day 1 and > 50 ´ 109 l–1 on day 8. These
non-conventional thresholds, which were allowed by the support
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myelosuppression and to achieve a dose-intensive CMF regimen.
In the event of myelosuppression on the planned day of drug
administration, treatment was delayed for 1 week. No dose reduc-
tions were scheduled for nadir values or intercurrent fever. Red
blood cell transfusion was administered for haemoglobin values 
< 6.5 mmol l–1.
Radiation therapy was administered in case of involvement of
more than three positive lymph nodes, extranodal tumour growth,
multifocal tumour or breast lymphangitis. Radiotherapy was
administered concomitantly with CMF chemotherapy.
Toxicity was recorded using the WHO criteria (WHO, 1979).
The total dose of the chemotherapeutic drugs was expressed as
the percentage of the actual amount administered divided by the
projected amount, in which each drug was given equal value. The
DI was given as a percentage of the total dose administered per
unit time (weeks), divided by the actual duration of treatment. The
study was approved by the Medical Ethical Committee and all
patients gave informed consent.
The c2 test (Mantel–Haenszel) was used for statistical analysis
with the exception of the analysis of the leucocyte counts related to
Figure 1. For this purpose Friedman’s test (two-way rank analysis)
was used together with Duncan’s test for correction of multiple
comparisons. The confidence intervals were 95%.
RESULTS
Patient characteristics
Over a period of 1 year, 23 women entered the study. Twenty-one
patients had undergone a modified radical mastectomy and two
patients breast-conserving surgery. Twenty-two patients had
lymph node involvement, two had more than four positive nodes,
one patient was node-negative. Six patients received loco-regional
radiation therapy, including two with breast conserving therapy.
The median start of the chemotherapy was 19 days (range 14–48)
and of radiotherapy 64 days after surgery (range 43–78 days). The
patients’ characteristics are shown in Table 1.
Dose intensity
Two patients did not receive all courses of chemotherapy. One
patient had fever with leukopenia and skipped course 4B. Another
patient did not receive the last course (6B) due to haematological
toxicity. A total of 274 out of 276 courses were completed. Table 2
shows the actually achieved DI as a percentage of the projected DI
(range 78–100%) and the actually achieved DI compared to 
‘classical’ CMF (range 111–143%). In 21 patients the actually
delivered DI was ³ 85% of the projected DI, which is the equiva-
lent of ³ 120% compared to ‘classical’ CMF.
Delay of treatment
Out of these 23 patients, ten received all treatment as planned;
delay of treatment occurred in 13 patients (57%). A total of 17
courses out of 274 (6.2%) were delayed for a median of 1 week
(range 1–3 weeks). The total delay was 23 weeks (5.6%) on a
projected total treatment duration of 414 weeks for all patients.
The reasons for delay of chemotherapy are listed in Table 3. Delay
for insufficient marrow recovery and for fever and infection were
the most important causes.
Toxicity
Figure 1 shows the median leucocyte count with ranges at the start
of the courses. Over time, the median leucocyte count on day 8
declined, suggesting cumulative toxicity. Moreover, the absolute
increase of leucocytes during G-CSF administration (i.e. the
reserve-capacity) declined. The relative increase of leucocytes
related to the nadir in these cycles, however, were not different.
Intensified intravenous CMF with G-CSF in breast cancer 1921
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Figure 1 Leucocyte count (median and range) at the start of each course
Table 1 Patient characteristics (n = 23)
Age (years)
Median 44
Range 26–55
Primary tumour
pT1 4
pT2 19
Axillary lymph nodes examined
Median 10
Range 1–16
Axillary lymph nodes involved
Median 1
Range 1–8
Surgical treatment
Modified mastectomy 21
Breast-conserving surgery 2
Locoregional radiotherapy 6
Table 2 Actually achieved dose intensity (DI) compared to ‘classical’ CMF
regimen
Achieved dose intensity Number of Achieved DI compared
(% of projected DI) patients to ‘classical’ CMF
DI 100% 9 DI 143%
DI 85%–100% 12 DI 120–143%
DI < 85% 2 DI < 120%
Median DI: 95% Total: 23 Median DI: 135%
(range 78–100%) (range 111–143%)Overall, these changes indicate a gradual fall in bone marrow
reserve capacity.
Thirteen out of 23 patients (57%) were at least once (range 1–3)
affected by fever grade 2 (temperature > 38.0°C) and were treated
by oral or i.v. antibiotics. Eleven patients (48%) were treated by
oral antibiotics (infection grade 2). Four out of 23 patients (17%)
had fever with neutropenia and were admitted for i.v. antibiotics
(infection grade 3). The time to the first episode of infection is
shown in Figure 2. One prophylactic transfusion of platelets was
given for grade IV thrombocytopenia without bleeding. Red blood
cell (RBC) transfusions were administered to 12 patients (52%) at
a median value of haemoglobin of 5.5 mmol l–1. The median
number of transfusions was 3 units (range 2–6), for a total of 45
units. Figure 3 shows the cumulative probability of the first RBC
transfusion during treatment.
The main toxicity related to the use of G-CSF was mild bone
pain in seven patients (mainly in the first two cycles during the last
days of G-CSF) and musculoskeletal pain in two patients and was
not a reason to withhold its administration.
Radiotherapy
Six patients received radiation therapy. All six patients received
the projected total dose. The actual achieved DI was for three
patients 100%, for two patients 95% and for one patient 90%.
Insufficient leucocyte recovery (leucocyte count ≤ 3  ´ 109 l–1)
occurred in 23 of 72 courses (32%) versus in 64 of 204 courses
(32%) without radiotherapy (ns). One patient treated with radio-
therapy was hospitalized for infection grade 3 and RBC transfu-
sion was administered to three patients (ns).
DISCUSSION
We have studied the feasibility of an accelerated CMF schedule
aiming to reach a higher dose intensity. The dose-intensification
was achieved by shortening the cycle interval and by slightly
increasing the dose of cyclophosphamide, supported by G-CSF.
The dose intensity for cyclophosphamide was 500 mg m–2 week–1
i.v., a factor 1.43 compared to the ‘classical’ CMF regimen 
(350 mg m–2 week–1 orally). The dose intensity for methotrexate
and 5-fluorouracil was 133% compared to the oral schedule. With
this modified schedule, the median actually achieved dose inten-
sity was 135% compared to the ‘classical’ CMF. Recently,
Goldhirsch et al concluded that the many variations in CMF regi-
mens did not improve results (Goldhirsch et al, 1998a, 1998b).
However, several studies have suggested that a higher dose or dose
intensity of chemotherapy may improve disease-free and overall
survival (Bonadonna and Valagussa, 1981; Hryniuk and Bush,
1984; Hryniuk and Levine, 1986; Hryniuk et al, 1987; Tannock et
al, 1988; Ang et al, 1989; Engelsman et al, 1991; Wood et al,
1994). Bonadonna and Valagussa (1981) suggested after a retro-
spective analysis, that the effectiveness of adjuvant CMF depends
on the total dose actually administered. CMF was only useful
when given ³ 85% of the planned dose (Bonadonna and
Valagussa, 1981). Wood et al reported the results of a prospective,
randomized trial of adjuvant cyclophosphamide, doxorubicin and
5-fluorouracil in three dose levels (Wood et al, 1994). The women
treated with a moderate or high dose intensity had a significantly
longer disease-free and overall survival than those treated with a
low dose intensity. Tannock et al reported a reduction in response
rate and overall survival in patients who received the lower (50%)
1922 AME Bos et al
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Table 3 Reasons for delay of chemotherapy
Number of courses Number of 
(total = 276) weeks delayb
Criteria for treatment delay: (´ 109 l–1)
Course A (day 1):
Leucocyte count ≤ 2.5 3 3
Platelet count ≤ 75 1 1
Both 1 2
Course B (day 8):
Leucocyte count ≤ 1.0 1 1
Clinical events:
Infection grade 2 6 8
Infection grade 3 3 4
Nausea/vomiting grade 3 1 1
Surgerya 13
Total 17 (6.2%) 23 (5.6%)
aSecondary mastectomy after breast-conserving therapy for extensive DCIS
(ductal carcinoma in situ). bThe projected cumulative time on treatment for all
patients is 414 treatment-weeks
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Figure 2 Time to the first episode of infection treated by antibiotics
Figure 3 Time to the first red blood cell (RBC) transfusionIntensified intravenous CMF with G-CSF in breast cancer 1923
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dose arm compared to the standard intravenous CMF in metastatic
disease (Tannock et al, 1988).
An advantage of giving cyclophosphamide i.v. is the possibility to
start G-CSF immediately after the second i.v. dose from day 8
onwards and thus shorten the interval between the cycles. Several
studies examining the route of administration have been published
(Engelsman et al, 1991; Lindeman et al, 1992). An EORTC random-
ized study has compared ‘classical’ CMF with i.v. CMF (cyclophos-
phamide 600 mg m–2, methotrexate 40 mg m–2 and 5-fluorouracil
600 mg m–2, all i.v. on day 1) in 254 eligible patients with metastatic
breast cancer (Engelsman et al, 1991). The response rate after ‘clas-
sical’ CMF was 48% compared with 29% for i.v. CMF, but in the
‘classical’ CMF a higher dose intensity was achieved.
In the present trial the criteria for delay of courses due to
myelosuppression were less restricted than in most adjuvant
breast cancer protocols, which was allowed by the support of G-
CSF. In the hypothetical case that the criteria would have been
chosen more stringent (e.g. leucocyte count > 3.0 ´ 109 l–1 and
platelet count > 100 ´ 109 l–1 on day 1 and leucocyte count > 2.0 ´
109 l–1 and platelet count > 75 ´ 109 l–1 on day 8), course A would
have been postponed 16 instead of 5 weeks (11.6% vs 3.6%) and
course B 41 weeks instead of once (29.7% vs 0.7%). This would
have resulted in 19 patients (83%) with delay of treatment and an
estimated achieved DI of 84% at most. The effect of G-CSF on DI
of standard oral adjuvant CMF in 123 patients with breast cancer
was studied by De Graaf et al. Without G-CSF the leucocyte
count on day one was ≤ 3 ´ 109 l–1 in 21% of the courses (De
Graaf et al, 1996). In our study, the leucocyte count was ≤ 3 ´ 109
l–1 in 32% of the courses. Besides, 17% of the patients had to be
treated with i.v. antibiotics and 52% of the patients needed RBC
transfusions. With the ‘classical’ CMF regimen RBC transfusions
are rarely given.
G-CSF was administered on days 9–18 and was not given
simultaneously with chemotherapy to avoid enhanced myelotoxi-
city (ASCO, 1994). Recently, Tjan-Heijnen et al reported that, in
small-cell lung carcinoma patients, stopping G-CSF administra-
tion 48 h before the next chemotherapy course increased
chemotherapy-associated leucopenia and thrombocytopenia,
implying a carry-over effect in the next cycles (Tjan-Heijnen et al,
1998). It might be that stopping G-CSF earlier would yield better
results.
Several investigators showed that radiotherapy could have a
negative effect on marrow recovery and on the dose intensity in
combination with chemotherapy (Holland et al, 1980; Cooper et
al, 1981; Levine et al, 1984; De Graaf et al, 1996). This was espe-
cially seen when G-CSF was administered in conjunction with the
radiotherapy, leading to additional delays for thrombocytopenia.
However, Pronzato et al did not find a negative effect of radio-
therapy on the dose intensity of adjuvant CMF (Pronzato et al,
1993). In our study, the subgroup of patients having received radi-
ation therapy had equal dose intensity and there was no difference
in infection rate. We can not therefore in this small group confirm
an adverse impact of radiotherapy.
We conclude that this modified i.v. CMF regimen carries
enhanced haematological toxicity with clinical sequelae (namely
fever, i.v. antibiotics and many RBC transfusions), but allows a
high dose intensity in a majority of patients. This dose-intensive
CMF schedule could be the basis for a randomized phase III study
to compare with ‘classical’ CMF. Such a study should also
examine dose-intensity, toxicity, cost and quality of life. It should
be possible to use erythopoietin for treatment of anaemia and
prophylactic antibiotics to prevent infections. Also, repeated
peripheral stem cell support could be used to achieve high dose
intensity with less haematological toxicity.
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